Study Summary:
This is a phase 3 randomized, double-blind, active comparator, placebo-controlled study of the efficacy and safety of 2 doses of cp-690,550 in patients with active rheumatoid arthritis on background methotrexate.
Qualified Participants Must:
• Be 18 years of age or older
•
Diagnosed with rheumatoid arthritis
•
Currently taking methotrexate but not receiving sufficient relief
Qualified Participants May Receive:
Study medication and study-related care at no charge. Compensation for time and travel may be provided.